<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/621CACAB-53EE-48C8-A5EF-69DA4FA58943"><gtr:id>621CACAB-53EE-48C8-A5EF-69DA4FA58943</gtr:id><gtr:name>Leibniz Association</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>MRC Centre for Inflammation Research</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/621CACAB-53EE-48C8-A5EF-69DA4FA58943"><gtr:id>621CACAB-53EE-48C8-A5EF-69DA4FA58943</gtr:id><gtr:name>Leibniz Association</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FDF8C76C-8825-40D1-BBD6-BFBDF5E5555C"><gtr:id>FDF8C76C-8825-40D1-BBD6-BFBDF5E5555C</gtr:id><gtr:firstName>Steve</gtr:firstName><gtr:surname>Anderton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C567C858-C3B2-43FB-BA28-EE022C38B6C9"><gtr:id>C567C858-C3B2-43FB-BA28-EE022C38B6C9</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>Anthony</gtr:otherNames><gtr:surname>O Connor</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1100084"><gtr:id>EAA4AFD2-3B7E-43D4-ADA0-9CFD5EF51184</gtr:id><gtr:title>The role of T-bet in Foxp3+ T regulatory cell-mediated protection from autoimmune inflammation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1100084</gtr:grantReference><gtr:abstractText>Between 5-10% of the UK population suffer with ?autoimmune diseases?, such as juvenile diabetes, rheumatoid arthritis and multiple sclerosis (MS). In these diseases the immune system becomes ?confused? and attacks the patient?s own tissues, causing damaging inflammation, e.g. in the pancreas (diabetes), the joints (arthritis), or in the brain (MS).

The inflammation is driven by white blood cells called T cells. Small numbers of these respond against the patient?s tissue and release pro-inflammatory molecules locally to attract other immune cells from the blood, causing more damage. These disease-causing T cells express ?controller genes? that drive the pro-inflammatory response. Counteracting these dangerous T cells, the body also possesses ?regulatory? T cells (Treg). Treg have many functions but, using a model of MS, we have shown that they can have very strong anti-inflammatory effects within the brain itself, leading to recovery from the disease. The healthy brain has very few Treg cells present. But when it is inflamed, Treg cells enter the brain from the blood to switch the inflammation off. Because these Treg cells are so powerful, there is great interest in trying to make their function stronger in patients with autoimmune disease. Using our MS model, we have been able to infuse Treg and efficiently reverse the disease. Our most recent work has looked at the genes that Treg express. In addition to the controller gene that determines their anti-inflammatory function, we were surprised to find that the Treg cells in the brain also express the controller gene (called T-bet) that is used by the damaging T cells that cause the disease. Treg cells outside the brain do not express T-bet. This novel finding suggests that the Treg cells specifically within the brain need to ?shadow? the damaging T cells in terms of which genes they express in order to reverse the disease. In this project we will test the ability of Treg cells that can, or cannot express T-bet to reverse the MS-like disease. This will be done in the natural recovery model and also in the therapeutic Treg infusion model. To understand how T-bet controls Treg function, we will identify what other genes the Treg cells express, when they do, or do not express T-bet. This project will therefore provide important new information on how Treg cells reverse autoimmune diseases and, we hope, will suggest new and better treatments that can harness their anti-inflammatory powers.</gtr:abstractText><gtr:technicalSummary>T regulatory (Treg) cells expressing the Foxp3 transcription factor are an essential component of immune tolerance. Treg function in multiple ways to prevent the development of autoimmune inflammation and can also induce the natural resolution of inflammation once it is established. This latter property makes new therapeutic approaches aimed at improving Treg function particularly appealing. Using murine experimental autoimmune encephalomyelitis (EAE) as a model of organ-specific (CNS) type 1 autoimmune inflammation, we have previously described that Treg accumulate in the CNS in response to inflammation and are absolutely essential to its natural resolution. These CNS Treg are remarkably suppressive (as assessed by ex vivo functional assays). We have also established therapeutic models in which we transfer myelin-responsive TCR transgenic Treg to protect against, or to cure ongoing EAE. These therapeutic studies revealed that Treg can readily express T-bet, a transcription factor primarily associated with T helper (Th)1 cells, a CD4+ population known to be pathogenic in EAE. Moreover, we find that the CNS Treg that trigger natural EAE resolution strongly express T-bet, whereas their counterparts from the peripheral lymphoid organs of the same mice are T-bet-. 
Our central hypothesis is that the induction of T-bet expression in Treg at sites of type 1 inflammation has two essential roles:- a) enabling efficient Treg-mediated suppression of Th1 effector function and b) inhibiting the potentially pro-inflammatory action of the Treg themselves. Furthermore, we propose that integrating T-bet expression as a component of Treg functional profile will provide maximal therapeutic potency. 
To test this hypothesis, our research aims are to:-
1) determine whether T-bet expression within CNS Treg is required specifically for their ability to suppress Th1-driven pathology during the natural resolution of CNS inflammation.
2) understand the impact of T-bet expression on the Treg transcriptional profile.
3) profile the functionality of T-bet-sufficient versus T-bet-deficient Treg extracted from the inflamed CNS.
4) assess whether T-bet expression is required for therapeutic Treg function in EAE.
5) explore whether we can enforce T-bet expression in Treg in vitro and in vivo. 
We shall interrogate our hypothesis by use of a unique collection of GM mice in which specifically Treg can or cannot express T-bet (i.e. the pathogenic T cell populations will be T-bet-sufficient). This project will therefore provide important new information on Treg biology and may open new avenues to harnessing their therapeutic potential.</gtr:technicalSummary><gtr:fund><gtr:end>2015-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>701479</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leibniz Association</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>German Rheumatism Research Centre (DRFZ)</gtr:department><gtr:description>B cells in autoimmune disease</gtr:description><gtr:id>1DBA3C1D-8953-4EA3-BC13-1E68B9E828C6</gtr:id><gtr:impact>PMID 16506290, 18354200, 18772002, 18437156, 19037227</gtr:impact><gtr:outcomeId>CDF3D6BDEDB-1</gtr:outcomeId><gtr:partnerContribution>Multiple interactions on T cell and B cell biology</gtr:partnerContribution><gtr:piContribution>Expertise in EAE and T cell biology/tolerance</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>F3CA15A8-A7FB-475A-AE86-C1919EB4A4CF</gtr:id><gtr:title>Adaptive immune responses in CNS autoimmune disease: mechanisms and therapeutic opportunities.</gtr:title><gtr:parentPublicationTitle>Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4e76615cc778430bf81c2ff45fd04cb"><gtr:id>b4e76615cc778430bf81c2ff45fd04cb</gtr:id><gtr:otherNames>McPherson RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1557-1890</gtr:issn><gtr:outcomeId>pm_15258_28_23568718</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDA00A04-424B-46AD-9EE8-175198EEE48C</gtr:id><gtr:title>T-bet Expression by Foxp3(+) T Regulatory Cells is Not Essential for Their Suppressive Function in CNS Autoimmune Disease or Colitis.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4e76615cc778430bf81c2ff45fd04cb"><gtr:id>b4e76615cc778430bf81c2ff45fd04cb</gtr:id><gtr:otherNames>McPherson RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5675e06d3b81e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C49F6B0F-220C-475A-8134-6407CE3886AA</gtr:id><gtr:title>Eliminating roles for T-bet and IL-2 but revealing superior activation and proliferation as mechanisms underpinning dominance of regulatory T cells in tumors.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/639b9cabc30209175d7feb03d9eaf8c2"><gtr:id>639b9cabc30209175d7feb03d9eaf8c2</gtr:id><gtr:otherNames>Colbeck EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>56dc6dd6b23f93.50566625</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F32A26B0-48D6-46DE-9EAD-40DD78138CA8</gtr:id><gtr:title>T-bet is essential for Th1-mediated, but not Th17-mediated, CNS autoimmune disease.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87b677d4d98cbb244cc46a69c9bbb7d6"><gtr:id>87b677d4d98cbb244cc46a69c9bbb7d6</gtr:id><gtr:otherNames>O'Connor RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>doi_15258__201343689</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A10FAB1-8E94-4EBB-8770-D391E997B039</gtr:id><gtr:title>Antigen-based immunotherapy (AIT) for autoimmune and allergic disease.</gtr:title><gtr:parentPublicationTitle>Current opinion in pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cabf9779147551945b5c5b457e27740a"><gtr:id>cabf9779147551945b5c5b457e27740a</gtr:id><gtr:otherNames>MacLeod MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-4892</gtr:issn><gtr:outcomeId>5675e5134beb9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>867AEEC2-8A94-4F7A-8E4C-7141F9DDF546</gtr:id><gtr:title>Exposure to inflammatory cytokines selectively limits GM-CSF production by induced T regulatory cells.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8717456a0d977976c926cece73eef386"><gtr:id>8717456a0d977976c926cece73eef386</gtr:id><gtr:otherNames>Reynolds BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>545fb22505ebe9.99899314</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>889263D8-A13A-43E1-8AD5-49EF70BC2482</gtr:id><gtr:title>Rapid reprogramming of epigenetic and transcriptional profiles in mammalian culture systems.</gtr:title><gtr:parentPublicationTitle>Genome biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8325dbf499f9df455860713307706458"><gtr:id>8325dbf499f9df455860713307706458</gtr:id><gtr:otherNames>Nestor CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1474-7596</gtr:issn><gtr:outcomeId>56dc6dd72bd621.98722740</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFAF1634-F8F8-43B0-BF21-571EBC49025B</gtr:id><gtr:title>Ischemic preconditioning in the liver is independent of regulatory T cell activity.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/358429590744fedcbb8c0669a5acd826"><gtr:id>358429590744fedcbb8c0669a5acd826</gtr:id><gtr:otherNames>Devey LR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15258_28_23185394</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B742CF96-5E64-443F-BDF4-7488CA5F56C9</gtr:id><gtr:title>Cutting edge: IL-6-dependent autoimmune disease: dendritic cells as a sufficient, but transient, source.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba3ff6ebd6b6261e1b34760ccb07c464"><gtr:id>ba3ff6ebd6b6261e1b34760ccb07c464</gtr:id><gtr:otherNames>Leech MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>545fbc560ed713.90920521</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E71088FB-C7DE-4B13-B7CE-962360BF0CD1</gtr:id><gtr:title>IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6aa1011d9efeb6a556d72153917cf8d7"><gtr:id>6aa1011d9efeb6a556d72153917cf8d7</gtr:id><gtr:otherNames>Shen P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>545fb288ab19b6.71809662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84E0FA5A-3591-42D8-B767-A0845A869F01</gtr:id><gtr:title>Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4(+) T cells tolerized by peptide immunotherapy.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4e76615cc778430bf81c2ff45fd04cb"><gtr:id>b4e76615cc778430bf81c2ff45fd04cb</gtr:id><gtr:otherNames>McPherson RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>5675de366c0ff</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5ACE6510-89C0-4882-BD79-52930311CFE3</gtr:id><gtr:title>Inflammation-associated genes: risks and benefits to Foxp3+ regulatory T-cell function.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87b677d4d98cbb244cc46a69c9bbb7d6"><gtr:id>87b677d4d98cbb244cc46a69c9bbb7d6</gtr:id><gtr:otherNames>O'Connor RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>585d580e21ca75.69261796</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B69EA68B-C87F-4F70-9201-145BC1DB5833</gtr:id><gtr:title>Induction of passive EAE using myelin-reactive CD4+ T cells.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4e76615cc778430bf81c2ff45fd04cb"><gtr:id>b4e76615cc778430bf81c2ff45fd04cb</gtr:id><gtr:otherNames>McPherson RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>545fb264183566.07088716</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0159B197-D680-4DFF-813D-2B48ED32DBF8</gtr:id><gtr:title>Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24b9c08d8e7240b7ae5713c774821124"><gtr:id>24b9c08d8e7240b7ae5713c774821124</gtr:id><gtr:otherNames>Serrels A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>5675ebf4f3d56</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100084</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>